ALSN News (online only)
Neuralstem reports that participants with limb-onset ALS who were early in their disease course had better outcomes in its trial
Posted on Wednesday, May 22, 2013 - 01:27, By: Amy Madsen
Recently announced data from a phase 1 clinical trial of NSI-566 neural stem cells in people with amyotrophic lateral sclerosis (ALS) show that a subset of trial participants had better outcomes than the others.
Newest clinic to be designated an MDA/ALS center is located at Louisiana State University (LSU) Health Sciences Center New Orleans School of Medicine
Posted on Tuesday, May 21, 2013 - 05:00, By: Amy Madsen
The Muscular Dystrophy Association has designated the MDA clinic at Louisiana State University Health Sciences Center School of Medicine in New Orleans as an MDA/ALS center. This brings the total number of these specialized clinics to 44.
Genervon Biopharmaceuticals has launched a phase 2 trial to test its experimental drug GM604 in people with amyotrophic lateral sclerosis
Posted on Thursday, May 16, 2013 - 17:29, By: Amy Madsen
A phase 2 clinical trial to test the experimental drug GM604 in people with amyotrophic lateral sclerosis (ALS) has opened at two trial sites in the United States. Enrollment is expected to begin soon.
Treatment with the naturally occurring hormone delayed symptom onset, increased life span and inhibited nerve-cell loss in the SOD1 research mouse model of amyotrophic lateral sclerosis
Posted on Friday, May 10, 2013 - 11:31, By: Amy Madsen
Melatonin, a naturally occurring hormone produced by the pineal gland, is best known for its role in regulating sleep.
An MDA-supported research team has identified compounds that may prevent nerve-cell loss caused by dysregulation of a critical cell survival mechanism
Posted on Tuesday, April 23, 2013 - 11:01, By: Amy Madsen
An MDA-supported research team has identified a series of compounds that appear to work both alone and in combination to protect the muscle-controlling nerve cells (motor neurons) that are lost in amyotrophic lateral sclerosis (ALS).
A $3.2 million grant, awarded through MDA's Augie's Quest research initiative, will help support ALS research at the nonprofit biotech ALS Therapy Development Institute through 2013
Posted on Thursday, April 18, 2013 - 06:00, By: Amy Madsen
MDA and the nonprofit biotech ALS Therapy Development Institute (ALS TDI) have extended their strategic research partnership through 2013. With the extension comes a $3.2 million MDA grant to help support the nonprofit biotech's continued progress toward developing treatments for amyotrophic lateral sclerosis (ALS).
Connect with MDA
Muscular Dystrophy Association — USA
National Headquarters
3300 E. Sunrise Drive
Tucson, AZ 85718
(800) 572-1717
©2013, Muscular Dystrophy Association Inc.
All rights reserved.
All of contents copyright 2013 MDA All rights reserved.
